Lumara Health Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lumara Health Inc.
Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
AbbVie posts solid quarter on strength of Skyrizi growth and continued US growth for Humira ahead of patent expiry. Imbruvica revenue continues to decline, however.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Other Names / Subsidiaries
- Ethex Corporation
- K-V Pharmaceutical Company (KV Pharmaceutical)
- Ther-Rx Corporation